Drug Trial Radar · NCT03485729
ONC201 in Recurrent or Metastatic Type II Endometrial Cancer Endometrial Cancer
Last checked: Nov 19, 2026Latest source record: Dec 24, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
27
Actual
Start
Mar 21, 2018
Primary completion
Jan 19, 2023
Study completion Jan 19, 2023
Sponsor
- Lead sponsor
- Jazz PharmaceuticalsJazz Pharmaceuticals (JAZZ)
- Sponsor type
- Industry
- Collaborators
- Oncoceutics, Inc.
- First posted
- Apr 2, 2018
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- Female only, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This was a Phase 2, Simon two-stage, non-randomized, open-label, 2-arm trial of dordaviprone (ONC201) in women with metastatic or recurrent Type II endometrial cancer who failed at least 1 prior chemotherapy regimen. Patients with histologically confirmed Type II endometrial cancer, including but not limited to serous, clear cell, carcinosarcoma, adenosquamous, and mixed histologies were eligible. The primary objective of this study was to determine the efficacy of dordaviprone (ONC201) in metastatic type II endometrial cancer. Note: This study was completed by predecessor company, Oncoceutics, Inc.
Conditions
- Endometrial Cancer Recurrent
Interventions
Dordaviprone (ONC201)Drug
625 mg dordaviprone (ONC201)
Primary outcomes
What the sponsor says the trial is designed to measure.
- Progression-Free Survival Rate at 2 MonthsTime frame: 2 months (8 weeks); from treatment initiation to 2 months (8 weeks) following treatment initiation
Locations
3 sites in 1 country. Site status is shown where the registry gives one.
Rutgers, The State University of New Jersey
New Brunswick, New Jersey
UNC Lineberger Comprehensive Cancer Center
Chapel Hill, North Carolina
Fox Chase Cancer Center
Philadelphia, Pennsylvania
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.